Biosimilar Resources

Biosimilars are biologic medicines that are highly similar to already approved reference products, offering comparable safety, efficacy, and quality at a reduced cost. Our resources provide information on the use, benefits, and regulatory guidelines of biosimilars to help healthcare professionals improve patient access and manage treatment costs effectively. To learn more about biosimilars and biologics visit AMCP's Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) at bbcic.org.

Featured Resources

See All in Biosimilars

Podcast March 1, 2023

The Buzz Around Biosimilars: AMCP’s Actions for 2023

2023 will be a pivotal year for biosimilar success or failure. Health care expert Fred Goldstein sits down with Stanton Mehr of Biosimilars Review & Report, to discuss what lies in store for biosimilars and AMCP’s biosimilar initiatives this year.

Podcast March 17, 2023

Humira Biosimilars are Here! What Now?

Health care expert Fred Goldstein sits down with Melissa Andel, principal and founder of CommonHealth Solutions, to discuss the long-awaited launch of Humira biosimilars and what Amgen’s pricing strategy means for patients and payers.

Webinars

Bracing for the Impact of Biosimilars: Navigating Terrain in the U.S. Market Landscape

Tuesday, Jun. 11, 2024 at 2-3pm ET

External Content February 14, 2020

Financial Incentives Prompt Managed Care, Not FFS Medicaid Programs to Use More Biosimilars and Generics

For two drugs with a branded product that had a large price increase, the market share of the related biosimilar or generic was higher among Medicaid MCOs not subject to preferred drug lists (PDLs) as compared to MCOs subject to PDLs and Medicaid FFS programs, according to a JMCP study.

External Content November 30, 2019

Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care

This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval surveillance of biologics and biosimilars by utilizing its distributed research network.

External Content November 14, 2019

Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evlauate Patterns of Care

This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval survellience of biologics and biosimilars by utilizing its distributed research network.

External Content September 26, 2019

BBCIC

The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.

Blog September 4, 2019

Biosimilars Could Be in Jeopardy if ACA is Invalidated

AMCP CEO Blog: AMCP’s roughly 8,000 members work diligently every day to improve patient care through the optimized use of medicines. As an organization, we also take a leading role in developing improvements to the overall delivery of care, which is no easy task given the size and complexity of our health care system.

Legislation & Regulation, Biosimilars

Practice Positions August 12, 2019

Generics

From the AMCP Policy Digest, AMCP's policies regarding generics programs.

Practice Positions August 12, 2019

Specialty Pharmacy/Biosimilars

From the AMCP Policy Digest, AMCP's policies regarding specialty pharmacy and biosimilars

Press Releases April 5, 2019

Managed Care and Specialty Pharmacy Professionals Identify Barriers and Solutions to Increasing Biosimilar Adoption

Press Release: From News&Views April 2019: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies.

Managed Care Practice Issues, Biosimilars, Specialty Pharmacy

Page March 22, 2019